BIOLIFE SOLUTIONS INC (BLFS)

Quarterly Report Filed: 2026-05-07

Key Insights

The filing shows significant corporate restructuring activity with multiple discontinued operations (SAVSU divested in October 2025, Global Cooling divested in Q1 2025, and PanTHERA acquisition in April 2025), indicating management is actively reshaping the company's portfolio and focusing on core operations.
The presence of convertible promissory notes and multiple series of preferred stock (Series A and Series E) in the capital structure suggests the company has been relying on debt and equity financing to fund operations and acquisitions, which may indicate capital constraints or dilution concerns for common shareholders.
The company maintains a diversified investment portfolio across money market funds, government securities, corporate debt, and other instruments as of Q1 2026, indicating management is preserving liquidity despite ongoing operational changes and restructuring activities.

Current Report Filed: 2026-05-07

Key Insights

BioLife Solutions announced Q1 2026 financial results on May 7, 2026, indicating the company is actively reporting operational performance to shareholders and the market.
The 8-K filing references a press release (Exhibit 99.1) containing unaudited Q1 2026 results and operational highlights, but the actual financial figures and performance metrics are not detailed in this SEC document itself.
The filing was signed by Troy Wichterman, Chief Financial Officer, suggesting stable leadership continuity at the company during this reporting period.
As a Nasdaq-listed company with a standard form 8-K filing for earnings disclosure, BioLife Solutions is maintaining compliance with SEC reporting requirements and market transparency standards.

Insider Trading Filed: 2026-04-10

Key Insights

Insider Aby J. Mathew, an EVP and Chief Scientific Officer, sold 515 shares of BioLife Solutions Inc. (BLFS) stock at $19.27 per share on April 8, 2026.
This sale represents a small portion (0.13%) of Mathew's total beneficial ownership in the company, which remains at 390,167 shares.
Insider transactions, especially sales, can provide insights into management's views on the company's prospects and valuation, though a single transaction should be interpreted cautiously.

Insider Trading Filed: 2026-04-10

Key Insights

Insider Todd Berard, Chief Marketing Officer, sold 293 shares of BioLife Solutions Inc. (BLFS) on April 8, 2026, representing a small fraction of his total holdings of 163,768 shares.
The share sale was to cover tax withholding obligations upon the release of restricted stock units, suggesting ongoing equity compensation and retention of a significant ownership stake.
This insider transaction does not appear to signal any material changes in the company's operations or outlook, as the sale amount is relatively modest.

Insider Trading Filed: 2026-04-10

Key Insights

Troy Wichterman, the Chief Financial Officer of BioLife Solutions Inc., disposed of 844 shares of the company's common stock on April 8, 2026 in order to satisfy tax withholding obligations.
Wichterman's remaining beneficial ownership of BioLife Solutions' common stock stands at 216,056 shares, indicating he continues to maintain a significant stake in the company.
The reported transaction appears to be a routine stock sale to cover tax obligations, rather than a broader change in Wichterman's investment in BioLife Solutions.

Insider Trading Filed: 2026-03-31

Key Insights

Karen A. Foster, the Chief Quality and Operations officer, sold 2,577 shares of BioLife Solutions Inc. (BLFS) on March 23, 2026 at an average price of $19.17.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, indicating a pre-planned sale of shares.
Following the reported transaction, Foster now holds 108,758 shares of BLFS directly, representing her beneficial ownership.

Insider Trading Filed: 2026-03-23

Key Insights

Roderick de Greef, the President and CEO of BioLife Solutions Inc., has disposed of 11,101 shares to satisfy tax withholding obligations, reducing his direct ownership to 733,746 shares.
The transaction was executed on March 19, 2026, and reported on the SEC Form 4 filing on March 23, 2026.
This insider selling activity may indicate de Greef's confidence in the company's near-term performance or a need to diversify his personal portfolio.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Todd Berard, who is the Chief Marketing Officer, disposed of 1,879 shares of the company's common stock through a share withholding transaction to satisfy tax obligations.
This transaction resulted in the reporting person holding 164,061 shares of the company's common stock, which represents their direct ownership in the company.
The transaction was executed on March 19, 2026, at a price of $19.12 per share.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Sean Werner, the Chief Technology Officer of BioLife Solutions Inc., disposed of 1,681 shares of common stock on March 19, 2026 to satisfy tax withholding obligations.
The reported transaction reduces Werner's direct beneficial ownership of BioLife Solutions Inc. common stock to 48,251 shares.
Insider selling, even for tax purposes, can be perceived negatively by investors and may signal potential concerns about the company's outlook.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person Troy Wichterman, who is the Chief Financial Officer, disposed of 3,749 shares of BIOLIFE SOLUTIONS INC (BLFS) common stock on March 19, 2026. This may indicate some level of insider selling activity.
The shares were disposed of at a price of $19.12 per share, which appears to be in line with the company's recent trading range.
Following the reported transaction, the reporting person still holds a significant position of 216,900 shares, suggesting they maintain a sizable stake in the company.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Sarah Aebersold, who is the Chief Human Resources Officer of BioLife Solutions Inc., disposed of 931 shares of the company's common stock on March 19, 2026.
The shares were disposed of to satisfy tax withholding obligations arising from the release of restricted stock units, indicating the reporting person's compensation is partially tied to equity incentives.
Following the reported transaction, the reporting person still holds 92,429 shares of BioLife Solutions' common stock, suggesting they maintain a significant ownership stake in the company.

Insider Trading Filed: 2026-03-23

Key Insights

Insider Karen A. Foster, the Chief Quality and Operations Officer, disposed of 1,907 shares of BioLife Solutions Inc. (BLFS) stock on March 19, 2026. This suggests potential insider selling activity.
The share disposal was made to satisfy tax withholding obligations arising from the release of restricted stock units, indicating a non-discretionary transaction.
Foster's remaining direct beneficial ownership of 111,335 shares indicates she still holds a significant stake in the company, suggesting continued alignment with shareholder interests.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Aby J. Mathew, an EVP and Chief Scientific Officer of BioLife Solutions Inc., disposed of 2,255 shares of the company's common stock, likely to satisfy tax withholding obligations arising from the release of restricted stock units.
The sale was executed at a price of $19.12 per share, resulting in the reporting person beneficially owning 390,682 shares of the company's common stock.
The transaction appears to be a routine, non-discretionary sale related to tax obligations and does not necessarily indicate a significant change in the reporting person's overall ownership or confidence in the company.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Karen A. Foster, who is the Chief Quality and Operations officer at BioLife Solutions Inc. (BLFS), sold 418 shares of common stock on March 3, 2026 at a price of $20.74 per share.
The sale was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of February 24, 2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Following the reported transaction, the reporting person still holds 210,665 shares of BioLife Solutions Inc. common stock directly.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Sean Werner, Chief Technology Officer of BioLife Solutions Inc., sold 111 shares of the company's common stock on March 3, 2026.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2022 to satisfy tax withholding obligations related to the vesting of restricted stock.
The reporting person still holds 49,932 shares of the company's common stock directly following the reported transaction.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Aby J. Mathew, who is the EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), sold 529 shares of common stock on March 3, 2026 at a price of $20.74 per share.
The sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective February 24, 2022, likely to satisfy tax withholding obligations in connection with the vesting of restricted stock.
The reporting person still holds 392,937 shares of BioLife Solutions' common stock, indicating they continue to maintain a significant ownership stake in the company.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Troy Wichterman, who is the Chief Financial Officer of BioLife Solutions Inc. (BLFS), sold 588 shares of the company's common stock on March 3, 2026 pursuant to a Rule 10b5-1 trading plan.
The sale was made to satisfy tax withholding obligations in connection with the vesting of restricted stock, indicating that the reporting person may be taking some profits or diversifying their holdings.
The reporting person still holds a significant stake of 220,649 shares in the company, suggesting they remain committed to BLFS despite the recent sale.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Sarah Aebersold, who serves as the Chief Human Resources Officer of BioLife Solutions Inc. (BLFS), sold 219 shares of the company's common stock at $20.74 per share.
The sale was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person, likely to satisfy tax withholding obligations in connection with the vesting of restricted stock.
The reporting person still holds 93,360 shares of the company's common stock directly, indicating they continue to maintain a significant stake in the company.

Insider Trading Filed: 2026-03-05

Key Insights

The reporting person, Todd Berard, who is the Chief Marketing Officer of BioLife Solutions Inc., sold 353 shares of the company's common stock at $20.74 per share on March 3, 2026.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in February 2022 to satisfy tax withholding obligations in connection with the vesting of restricted stock.
Following the reported transaction, the reporting person still holds 165,940 shares of BioLife Solutions' common stock directly.

Current Report Filed: 2026-03-02

Key Insights

BioLife Solutions, Inc. issued an investor presentation on March 2, 2026, which provides an update on the company's business and financial performance.
The presentation is available on the company's website, allowing investors to access the latest information about BioLife Solutions.
Investors should review the presentation to understand the company's current developments and future plans.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information